SCHEMBL1980615

SCHEMBL1980615

CS(=O)(=O)NCc1ccc(Oc2ccc3c(c2)S(=O)(=O)NCCN3)cc1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.38
GRIA2 P42262 8/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KMT2A Q03164 1/20 0.35
SCN9A Q15858 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
MMP2 P08253 1/20 0.32
MMP8 P22894 1/20 0.32
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32
TSHR P16473 1/20 0.32
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1980618 0.88 CNR2 (0.39) CNR2SLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL1967915 0.77 GRIA2 (0.53) GRIA2MMP2
SCHEMBL1977428 0.76 GRIA2 (0.40) GRIA2
SCHEMBL1971790 0.76 GRIA2 (0.40) GRIA2KMT2AMMP2
Hydrochloric Acid SCHEMBL2811105 0.75 GRIA2 (0.40) GRIA2KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL1978280 0.75 GRIA2 (0.44) GRIA2SLC6A2SLC6A3SMN1; SMN2NPC1
SCHEMBL5479962 0.74 GRIA2 (0.52) CNR2GRIA2SLC6A2SLC6A4SLC6A3
SCHEMBL5479896 0.74 GRIA2 (0.48) CNR2GRIA2SLC6A2SLC6A4SLC6A3
SCHEMBL5481531 0.74 GRIA2 (0.48) CNR2GRIA2SLC6A2SLC6A4SLC6A3
SCHEMBL1981334 0.73 CA2 (0.54) GRIA2KMT2AMMP2KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236790-B2 Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATORIES SERVIER (FR) 2012-08-07 US disclosed
EP-2246339-B1 Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors SERVIER LAB (FR) 2011-06-22 EP disclosed
EP-2246339-A1 Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors Les Laboratoires Servier (FR) 2010-11-03 EP disclosed
US-20100240635-A1 Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240635-A1 Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them GRIN1, GRIN2B, GRIN3A CNR2 37/4885GRIA2 45/4885SLC6A2 687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.